摘要: |
神经纤维瘤是整复外科最常见的良性皮肤软组织肿瘤之一,但约8%~13% 的神经纤维瘤存在恶变风险。研究提示血管新生对神经纤维瘤的进展和恶变起着重要的促进作用,而抗血管新生药物在神经纤维瘤的相关研究中也充分显示出潜在的临床应用价值。本文主要对神经纤维瘤的血供特点、血管新生机制以及抗血管新生靶向治疗的研究进展进行综述。 |
关键词: 神经纤维瘤 血管新生 治疗 |
DOI:10.12025/j.issn.1008-6358.2019.20190754 |
分类号: |
基金项目:上海市青年拔尖人才开发计划,上海交通大学医学院附属第九人民医院青年医师协同创新团队(QC201803) |
|
Angiogenesis and anti-angiogenesis targeted therapy in neurofibroma |
GU Yihui,REN Jieyi,LI Qingfeng,WANG Zhichao
|
Department of Plastic and Reconstructive Surgery,Shanghai Ninth People’s Hospital,Shanghai Jiaotong University School of Medicine
|
Abstract: |
Neurofibroma is one of the most common clinical manifestations in Neurofibromatosis Type 1, among which plexiform neurofibroma has about 8%-13% risk of malignant transformation. Previous researches suggest that angiogenesis plays an important role in the progression and malignancy of neurofibroma, while the anti-angiogenesis drugs have also demonstrated their potential clinical value in neurofibroma. In this paper, the blood supply characteristics of neurofibroma, the mechanism of angiogenesis and the research progress of anti-angiogenesis targeted therapy in neurofibroma were reviewed. |
Key words: Neurofibromatosis Angiogenesis Treatment |